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Introduction
Musculoskeletal injuries are the most common cause 
of severe, chronic pain and physical disability and account 
for the majority of all sport-related injuries1-3. Regardless 
of the mechanism of the injury, the healing process 
progresses through a constant series of overlapping 
phases resulting in the restoration of anatomic continuity 
and function4-6. These phases are controlled by complex 
and dynamic molecular mechanisms involving local and 
systemic factors interacting with many different cell 
types recruited to the injured site from the surrounding 
tissues and/or circulation. There is abundant evidence 
suggesting that growth factors may play a key role 
in the healing process, especially in the early stages 
of inflammation7-12. These observations constituted 
the basis for the use of platelet-rich plasma (PRP) in 
several circumstances, all of them characterised by the 
need to activate, modulate, accelerate or ameliorate 
the process of tissue repair. Clinically, it has been 
reported that the application of PRP to injured muscles 
can reduce symptoms and shorten the recovery period, 
allowing early mobilisation13. These observations have 
been confirmed in animal models using both PRP14 and 
platelet-rich fibrin matrix15. Despite the reported clinical 
successes and the many studies demonstrating the 
biological efficacy of isolated growth factors16-19, there 
is still a paucity of data on the biological mechanisms 
underlying the activity of PRP during the muscle healing 
process. Moreover, the review of the literature reveals 
a lack of standardisation in both the preparation of PRP 
and its application20,21. These observations may explain 
the variability in clinical and experimental results 
obtained in different studies22. Finally, the impact of the 
use of growth factors should be considered in the light of 
anti-doping regulations. Indeed the World Anti-Doping 
Agency (WADA) included intramuscular injection of 
PRP among their 2010 list of prohibited substances23, 
then allowed its use in the current 2012 list24. This 
Background. There is abundant evidence suggesting that growth factors may play a key role 
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underlying the activity of platelet-rich plasma during the process of muscle healing. The aim of this 
study was to analyse the early effects of platelet- rich plasma in an easily reproducible animal model.
Materials and methods. Wistar male adult rats (n =102) were used in this study. The muscle lesion 
was created with a scalpel in the flexor sublimis muscles. Platelet-rich plasma was applied immediately 
after surgery. Treated, untreated and contralateral muscles were analysed by morphological evaluation 
and western blot assay.
Results. Leucocyte infiltration was significantly greater in muscles treated with platelet-rich 
plasma than in both untreated and contralateral muscles. The latter showed greater leucocyte infiltration 
when compared to the untreated muscles. Platelet-rich plasma treatment also modified the cellular 
composition of the leucocyte infiltration leading to increased expression of CD3, CD8, CD19 and 
CD68 and to decreased CD4 antigen expression in both platelet-rich plasma treated and contralateral 
muscles. Blood vessel density and blood vessel diameters were not statistically significantly different 
between the three groups analysed. 
Discussion. The results of this study showed that treatment with platelet-rich plasma magnified 
the physiological early inflammatory response following a muscle injury, modifying the pattern of 
cellular recruitment. Local platelet-rich plasma treatment may exert a direct or, more plausibly, indirect 
systemic effect on healing processes, at least in the earliest inflammatory phase.
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modification was made despite the suggested systemic 
effect of locally injected growth factors described by 
some authors25. The aim of this study was to analyse 
the early effects of PRP in an easily reproducible animal 
model, and to verify whether local administration of PRP 
may exert a systemic effect on contralateral muscles.
Materials and methods
Animals and surgery
Wistar male adult rats (n =102), weighing 
approximately 250 g each, were used. Eighteen 
animals were used for the set up of the experimental 
model (i.e. blood collection, PRP preparation, muscle 
lesion and PRP injection in the injured site). Animals 
were sacrificed 1, 3 and 7 days postoperatively for 
macroscopic and microscopic assessment of the healing 
of the lesion. Fifty-four rats were sacrificed in order to 
investigate the time course of leucocyte infiltration and 
to study its characteristics at 1, 2, 3, 4, 5 and 6 days 
after the injury. To evaluate a possible systemic effect, 
an injury was made to the right flexor muscles of 18 rats 
and immediately treated with PRP (treated group), 18 
animals, used as controls, were subjected to the same 
muscle injury and left untreated (control group), 18 rats 
were subjected to muscle injury in both anterior limbs; 
the injury to the right limb was treated with PRP while 
the injury on the left remained untreated (contralateral 
group). Finally 30 rats were used for western blot 
analysis in order to evaluate the composition of the 
leucocyte infiltration: 15 animals were sacrificed 2 days 
after surgery (5 in the control group, 5 in the treated 
group and 5 in the contralateral group). The remaining 
15 animals were sacrificed 5 days after surgery (5 in 
the control group, 5 in the treated group and 5 in the 
contralateral group). All animals were kept in a cage in 
a room with controlled temperature and humidity, with 
a light/dark cycle of 12/12 hours, and allowed food and 
water ad libitum. Animals were operated under general 
anaesthesia by intramuscular injection of tiletamine + 
zolazepam (Zoletil) 3 mg/kg. The surgical procedures 
were performed with the aid of a surgical microscope 
(Zeiss OPMI7, Jena, Germany). A longitudinal incision 
was performed on the right anterior limb (or both anterior 
limbs) from the elbow region to the wrist in order to 
access the flexor sublimis muscles of the upper joint of 
the digits. The muscle was then injured transversely and 
medially using a scalpel. The wedge-shaped lesion was 
3 mm long, 2 mm wide and 3 mm deep. Immediately 
after the incision, the injury sites of the treated animals 
were filled with PRP. Although the type of surgery 
adopted ensured very limited post-operative discomfort 
and virtually no signs of animal suffering, all rats 
were treated with a pain killer (Finadyne administered 
intramuscularly at a dose of 2.5 mg/kg/12 h). The 
decision to give all animals the analgesic, independently 
of the presence of signs of suffering, was made with the 
intent of obtaining the same conditions in the different 
experimental settings since the use of anti-inflammatory 
drugs may affect both the healing process and the early 
inflammatory response26. All procedures were approved 
by the local Animal Care Committee, supervised by 
a veterinarian, and performed in accordance with the 
Local Ethical Committee's rulings and the European 
Communities Council Directive of 24 November 1986 
(86/609/EEC).  
Blood collection and preparation of platelet-rich 
plasma
Blood was collected by intracardiac puncture of the 
anaesthetised rats immediately before the surgical injury 
to the muscle. Briefly, a needle (21G) was inserted at 
the base of the sternum at a 20° angle just lateral of the 
midline. The intracardiac blood (3-3.5 mL) was slowly 
withdrawn into a syringe containing 1 mL of 3.8% 
sodium citrate. Blood was then transferred into sterile 
tubes containing sodium citrate and underwent a first 
centrifugation at 220 g for 15 minutes. To objectively 
determine the number of platelets and investigate the 
presence of other blood cells, a complete blood count 
was performed using a cell counter ADVIA 2021 
(Bayer, Leverkusen, Germany) on a small amount of 
the plasma layer obtained after the first centrifugation 
(the white blood cell content was always very low: 
(0.01±0.082)103/mm3, P-PRP subtype27). A second 
centrifugation at 1,270 g for 5 minutes allowed the 
platelets to fall to the bottom of the tube. The pellet 
was re-suspended in 100 L of plasma (the platelet 
concentration was always at least four times greater than 
the initial value). This platelet enriched preparation was 
activated with 20 L of 10% calcium chloride (Braun, 
Melsungen, Germany, 1,000 IE/mL CaCl2-2SG) at 37 
°C and, after jellification, immediately inserted using 
tweezers into the injured muscle of the same animals 
from which the blood had been drawn. The wound was 
then sutured and washed with saline solution.
Light microscopy
Muscles were fixed in 4% paraformaldehyde for 2-4 
hours and then washed in phosphate-buffered saline. 
Samples were dehydrated in an ascending series of 
graded alcohol, cleared in xylene and embedded in 
paraffin. Series of longitudinal and transverse sections of 
the muscles were obtained using a microtome RM2135 
(Leica Microsystems, Wetzlar, Germany). The following 
histological stains were used: haematoxylin and eosin, 
Masson's trichrome and May Grunwald-Giemsa. 
Morphoquantitative stereological analysis
Morphoquantitative stereological analysis was 
performed on serial sections stained with haematoxylin 
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PRP effects on muscle healing
and eosin. A microscope equipped with a digital camera 
DM4000B DFC320 and software for processing 
images IM50 (Leica Microsystems) was used28. For the 
stereological quantification of the volume of the infiltrate, 
a design-based systematic-random sampling scheme and 
the Cavalieri method were adopted29,30. In addition, the 
unbiased counting frame method31 was used to estimate 
the total number of leucocytes infiltrating the muscle as 
well as the blood vessel density in the area of infiltration.
 
Immunohistochemistry and confocal laser microscopy 
Sections were permeabilised, blocked [0.3% triton 
X-100, 10% normal goat serum/0.1% NaN3, for 1 h] and 
processed for immunohistochemical studies. Sections 
were incubated overnight in primary antibody and 
visualised using a solution containing the appropriate 
secondary antibody. The primary antibody used was 
MyoD (BD Pharmingen, Franklin Lakes, New Jersey). 
Goat anti-mouse IgG Alexa-Fluor-568-conjugated and 
Fluorescein goat anti-mouse IgG1 (Life Technologies, 
Paisley, UK) were used as secondary antibodies. Finally, 
samples were mounted with a Dako fluorescent mounting 
medium and analysed using a LSM 510 confocal laser 
microscopy system (Zeiss, Jena, Germany) equipped 
with an inverted Axiovert 100M microscope.
Western blot assay
Samples of muscle tissue (200-300 mg) were 
homogenised and lysed in RIPA buffer (25 mmol/L Tris-
HCl pH 7.6, 150 mmol/L NaCl, 1% NP-40, 1% sodium 
deoxycholate, and 0.1% sodium dodecyl sulphate) 
supplemented with Halt™ Protease Inhibitor Cocktail. 
Whole cell lysates were obtained by subsequent lysis with 
politron. Protein concentrations were determined using a 
Bradford Protein Assay Kit with bovine serum albumin 
as a standard. Protein extracts (100 μg) were subjected 
to 10% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis and transferred to a Protran nitrocellulose 
membrane. This membrane was incubated with CD3 
(abcam, Cambridge, UK), CD4 (Abbiotec, San Diego, 
California, USA), CD8 (Abbiotec), CD19 (Abbiotec), 
CD68 (Abbiotec) and MyoD (BD Pharmingen) at 4 
°C overnight. The membrane was washed with TBST 
buffer (20 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 
and 0.1% Tween-20), incubated with a secondary goat 
anti-rabbit (Santa Cruz Biotechnology, Dallas, Texas, 
USA) and goat anti-mouse (Santa Cruz Biotechnology) 
for 2 h at room temperature. The immuno-reacting bands 
were visualized by exposing the membranes to Kodak 
X-OMAT films. Densitometry and quantification were 
performed using the ImageJ software.
Statistical analysis
Database management and all statistical analyses 
were performed using the Statistica 6 for Windows 
software package (Statsoft Inc., Tulsa, OK, USA). 
Differences between means were assessed with 
a two-tailed Student's t test fixing the level of 
statistical significance to P ≤0.05. Correlations between 
quantitative variables were calculated by Pearson's r 
test. The null hypothesis of no correlation (ρ =0) was 
tested using the Fischer transformation. Results were 
considered statistically significant when P was <0.05. 
The comparisons among the groups examined (control 
vs treated vs contralateral) were evaluated by analysis 
of variance (ANOVA) and a post hoc Bonferroni's test 
for multiple comparisons. 
Results
Experimental set up of the muscle injury model
Macroscopic observation allowed us to establish the 
timing of muscle recovery following the lesion, which 
was particularly early in the selected experimental 
model. Indeed, 3 days after the lesion the wound 
appeared to be almost completely closed (the edges 
of the wound were almost completely adherent) and 
at 7 days the muscle appeared very similar to a non-
injured muscle. Since the physiological regenerative 
process was extremely rapid and at 7 days after its 
creation the lesion was no longer macroscopically 
detectable, we decided to limit the timing of the 
analytical determinations to the first 6 days after the 
muscle injury even if, microscopically, a very small 
leucocyte infiltration was still present 30 days after 
the injury (Figure 1).
Figure 1 - Optical microscopy images of control (CT) and treated 
(TR) muscles at 30 days after surgery. Magnification, 
2.5X; haematoxylin and eosin staining. 
Light microscopy
Figures 2 and 3 show representative microscopic 
pictures taken at different postoperative time points 
from the control, contralateral and treated groups. 
The leucocyte infiltration around the lesion was 
clear and appeared to increase over time until day 5 
after the surgical injury. Seven days after the injury, 
scar tissue completely closed the wound and the 
leucocyte infiltration progressively spread away from 
the lesion site.
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Volume of the leucocyte infiltration
The longitudinal sections enabled us to quantify 
the total volume of the leucocyte infiltration around 
the site of the lesion (Figure 4). The volume of the 
leucocyte infiltration, in the group treated with PRP was 
significantly greater than that in both the control and the 
contralateral groups.
Significant differences also emerged when analysing 
the infiltration volume of the contralateral samples. 
The leucocyte infiltration in the contralateral group 
was greater than that in control group. Thus suggesting 
intermediate values between the treated and the 
untreated samples when considering the immediate 
inflammatory response. 
Number of cells
When considering the total number of white 
blood cells infiltrating the injury site (Figure 5), the 
stereological analysis confirmed that the number of 
leucocytes was greater in the treated samples than in 
the other two groups. It is interesting that the number 
of cells infiltrating the muscles of the contralateral 
group showed a distinct behaviour when compared to 
the control group. Indeed, cells were more abundant in 
the first 3 days and then this increase reversed during 
the following days. 
Composition of the leucocyte infiltrate
When considering the composition of the leucocyte 
infiltration, there were slightly more lymphocytes and 
monocytes in the muscles treated with PRP than in the 
control and contralateral groups. 
Blood vessel density and diameter
With regard to the number of blood vessels in the 
area of the lesion, the microscopic analysis at 10X 
magnification showed a not statistically significant 
increase in the number of vessels in the samples treated 
with PRP when compared to the untreated muscles and 
to contralateral ones (Figure 6). Similarly, the analysis 
of the diameter of blood vessels showed that there were 
no statistically significant differences among the three 
groups considered.
Protein assay
PRP treatment modified the cellular composition of 
the leucocyte infiltration leading to increased expression 
of CD3, CD8, CD19 and CD68 in the treated and 
contralateral muscles when compared to the control ones 
(Figure 7). In contrast, CD4 expression was decreased 
in both the PRP-treated and contralateral muscles in 
Figure 2 - Optical microscopy images of control (CT), treated 
(TR) and contralateral (CL) muscles at 6 days after 
surgery. Magnification, 2.5X; haematoxylin and 
eosin staining.
Figure 3 - Optical microscopy images of treated muscles at 
2 and 5 days. Longitudinal (B, D) and transverse 
(A, C) sections at magnification 2.5X (B, C, D) 
and 10X (A); haematoxylin and eosin staining.
Figure 4 - Leucocyte infiltration volume. *: P ≤0.05; 
**: P ≤0.01; ***: P ≤0.001.
Figure 5 - Number of cells. *: P ≤0.05; **: P ≤0.01; 
***: P ≤0.001.
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comparison to the expression in the control samples 
(Figure 7). Again, values in contralateral muscles 
were intermediate between those in the treated and the 
untreated samples. Indeed, CD3, CD8, CD19 and CD68 
expression was higher in contralateral muscles than in 
untreated muscles but lower than that in PRP-treated 
muscles. Similarly, CD4 expression in contralateral 
muscles was lower than that in control samples but 
higher than that in PRP-treated samples.
Immunohistochemistry and western blot analysis 
showed higher expression of MyoD antigen 2 and 5 
days after the surgically induced lesion in the treated 
group when compared to the others two groups but this 
difference was statistically significant only at 2 and 5 
days after surgery in the following comparisons: treated 
vs control (P ≤0.01); treated vs contralateral (P ≤0.05) 
and treated vs control (P ≤0.05) (Table I, Figure 8).
Discussion
The results of the present study showed that 
PRP treatment magnifies the physiological early 
inflammatory response following a muscle injury, with 
a concomitant modification of the pattern of cellular 
recruitment. Moreover, it has been clearly demonstrated 
that PRP treatment may exert, directly or, more plausibly, 
indirectly, systemic effects. 
Physiologically, during the early inflammatory 
phase, it has been demonstrated that blood vessels 
are naturally torn, and consequently, blood-borne 
inflammatory cells gain direct access to the site of 
injury32,33. The beginning of the inflammatory response 
is amplified by the release of various substances by 
satellite cells and necrotic regions of the injured muscle 
fibres, which serve as chemoattractants in order to 
facilitate the transition of pro-inflammatory cells from 
the blood vessels at the site of injury32,34,35. Within the 
injured muscle, fibroblasts and macrophages are then 
activated, producing additional chemoattractants. In 
addition, most tissues contain growth factors stored 
in an inactive form to be used in case of immediate 
need36. It has been clearly shown in numerous studies 
that during the acute phase following a muscle injury, 
polymorphonuclear leucocytes are the most abundant 
cells present in the area of the lesion5,37-40, but that within 
the first days these cells are replaced by monocytes. In 
accordance with the basic principles of inflammation, 
monocytes are then actively involved in proteolysis 
and phagocytosis of necrotic material5,32,41,42. This 
process is highly specific and is aimed to preserve the 
cylinders of the basal lamina surrounding the necrotic 
Figure 6 - Vessel density.
Figure 7 - Analysis of cell types and subtypes in the leucocyte 
infiltrate at 2 and 5 days in the three groups analysed 
(TR: treated, CT: control and CL: contralateral).
Table I - Analysis of MyoD protein expression at 2 and 5 days in the three study groups.
2d 
TR vs CT
2d
CL vs CT
2d 
TR vs CL
5d 
TR vs CT
5d 
CL vs CT
5d 
TR vs CL
MyoD ** ns * ns * *
 2d TR 2d CT 2d CL 5d TR 5d CT 5d CL
MyoD 33,02±2,86 13,2±1,70 16,72±2,39 15,49±5,57 13,66±1,42 8,82±1,66
Legend   TR: treated, CT: control and CL: contralateral. *: P ≤0.05; **: P  ≤0.01.
Figure 8 - A. MyoD muscle protein expression at 2 and 5 days 
in the three groups analysed (TR: treated, CT: control 
and CL: contralateral). B. Immunohistochemistry 
analysis (MyoD+) in treated muscle at 2 (left) and 
5 days (right) after surgery.
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parts of the muscle fibres to be used as scaffolds in 
which the satellite cells can begin the formation of 
new muscle fibres5,43,44. Despite a huge amount of data 
regarding the effects of different isolated growth factors 
on muscle healing processes18,19,45, little is known about 
the mechanism by which plasma preparations with 
high concentrations of growth factors can modulate 
the inflammatory response25. Moreover, a review of the 
literature reveals a lack of standardisation with regards to 
both the preparation and the administration of PRP which 
may explain the inconsistent clinical and experimental 
results obtained in different studies46-49. A second 
important limitation derives from the fact that the vast 
majority of human studies have been performed on small 
samples usually with very small numbers of evaluable 
controls7,45,50. Most of the studies do not, therefore, have 
sufficient statistical power to support the adoption of the 
tested approach in clinical routine50. The results of the 
present study, in which an easily reproducible animal 
model was used, demonstrated that early PRP treatment 
significantly amplifies the physiological inflammatory 
response, as suggested by some authors, and modifies the 
pattern of inflammatory cell recruitment when compared 
to a physiological response to a muscle injury51. These 
observations contrast with those of Gigante et al. who, 
in their study performed on Wistar rats treated with 
platelet-rich fibrin matrix, did not observe any effect on 
inflammation15. This discrepancy may be partially due to 
the different preparations used, once again highlighting 
the need for standardisation of PRP preparation and 
administration before its adoption in clinical routine. 
The absence of significant differences in both blood 
vessel density and diameter among the three groups 
considered in this study suggest that PRP is not able 
to stimulating neo-angiogenesis in muscle directly. 
Again, these findings contrast with those of other studies 
performed with different PRP preparations15 or carried 
out on different tissues52. It is possible that different 
tissues may have different biological responses to PRP 
administration and that different PRP preparations may 
induce different biological pathways. These issues 
certainly need further assessment.
The higher expression of MyoD in treated samples 
observed on days 2 and 5 after surgery suggests that 
PRP may generate a myogenic response during the early 
phases of the regenerative process. This observation 
confirms the findings of other studies in animal 
models suggesting that muscle regeneration occurs in 
the early phase of healing and that PRP can stimulate 
myogenesis14,15,19. 
Taken together, these observations may have 
some immediate clinical translations. Indeed, the 
demonstrated modulation of the inflammatory response 
may explain the pain reduction usually observed 
after PRP administration and account for the early 
mobilisation of treated patients16,53,54.
To assess a potential systemic effect of PRP, 
"contralateral" muscles were analysed. These samples 
showed an intermediate response between the control 
group and the treated one. It does, therefore, seem that 
PRP administration may exert a systemic effect when 
healing processes are concerned, at least during the 
very first stages of inflammation. Considering the short 
half-life of growth factors, in the order of minutes55, it is 
difficult to consider that growth factors released locally 
by platelets may act on contralateral injured muscle. This 
observation agrees with the findings of recent studies 
in which the systemic levels of some growth factors, 
such as vascular endothelial growth fact and epidermal 
growth factor, were modified within 24 hours after 
PRP administration25,56. Further studies are needed to 
clarify this issue, with particular regard to anti-doping 
purposes23,24.
In conclusion, the results of the present study 
confirmed that PRP is a promising treatment for muscle 
injuries but that there are still unresolved issues. Further 
experimental studies are needed to fully understand the 
local and systemic mechanisms of action before using 
PRP in routine clinical practice. The easy reproducibility 
of the model used in this study has allowed us to create 
a solid foundation on which future studies will be 
carried out in order to deepen the understanding of 
the molecular dynamics of the inflammatory process 
modulated by PRP administration as well as the early 
myogenic response.
Acknowledgements
This study was supported by a grant from the 
Ministry of Health of Italy - Commission for the 
Surveillance of Doping (CVD) and by a grant from the 
World Anti-Doping Agency (WADA). 
The Authors state that they have no professional 
relationships with companies or manufacturers that will 
benefit from the results of the present study.
The Authors declare no conflicts of interest.
References
1) Beiner JM, Jokl P. Muscle contusion injuries: current treatment 
options. J Am Acad Orthop Surg 2001; 9: 227-37.
2) Garrett WE. Muscle strain injuries. Am J Sports Med 1996; 
24: S2-8.
3) Järvinen M, Lehto MUK. The effect of early mobilization 
and immobilization on the healing process following muscle 
injuries. Sports Med 1993; 15: 78-89.
4) Crisco JJ, Jokl P, Heinen GT, et al. A muscle contusion injury 
model: biomechanics, physiology, and histology. Am J Sports 
Med 1994; 22: 702-10.
5) Hurme T, Kalimo H, Lehto M, et al. Healing of skeletal muscle 
injury: an ultrastructural and immunohistochemical study. Med 
Sci Sports Exerc 1991; 23: 801-10.
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
s227
Blood Transfus 2014; 12 Suppl 1: s221-8 DOI 10.2450/2013.0275-12
PRP effects on muscle healing
6) Kalimo H, Rantanen J, Järvinen M. Muscle injuries in sports. 
Baillieres Clin Orthop 1997; 2: 1-24. 
7) Foster TE, Puskas BL, Mandelbaum BR, et al. Platelet-rich 
plasma: from basic science to clinical applications. Am J 
Sports Med 2009; 37: 2259-72.
8) Schnabel LV, Mohammed HO, Miller B, et al. Platelet rich plasma 
(PRP) enhances anabolic gene expression patterns in flexor 
digitorum superficialis tendons. J Orthop Res 2007; 25: 230-40.
9) Schmidt MB, Chen HE, Lynch SE. A review of the effects of 
insulin-like growth factor and platelet derived growth factor 
on in vivo cartilage healing and repair. Osteoarthr Cartil 2006; 
14: 403-12.
10) Best TM, Shehadeh SE, Leverson G, et al. Analysis of 
changes in RNA levels of myoblast and fibroblast-derived 
gene products in healing skeletal muscle using quantitative 
reverse transcription-polymerase chain reaction. J Orthop 
Res 2001; 19: 565-72.
11) Burkin DJ, Kaufman SJ. The α7β1 integrin in muscle 
development and disease. Cell Tissue Res 1999; 296: 183-90.
12) Chargé SBP, Rudnicki MA. Cellular and molecular regulation 
of muscle regeneration. Physiol Rev 2004; 84: 209-38.
13) Sampson S, Gerhardt M. Platelet rich plasma injection grafts 
for musculosketal injuries: a review. Curr Rev Musculosketal 
Med 2008; 1: 165-74.
14) Hammond JW, Hinton RY, Curl LA, et al. Use of autologous 
platelet-rich plasma to treat muscle strain injuries. Am J Sports 
Med 2009; 37: 1135-42.
15) Gigante A, Del Torto M, Manzotti S, et al. Platelet rich fibrin 
matrix effects on skeletal muscle lesions: an experimental 
study. J Biol Regul Homeost Agents. 2012; 26 :475-84.
16) Sánchez M, Anitua E, Azofra J, et al. Comparison of surgically 
repaired Achilles tendon tears using platelet-rich fibrin 
matrices. Am J Sports Med 2007; 35: 245-51.
17) Akeda K, An HS, Okuma M, et al. Platelet-rich plasma 
stimulates porcine articular chondrocyte proliferation and 
matrix biosynthesis. Osteoarthr Cartil 2006; 14: 1272-80.
18) Menetrey J, Kasemkijwattana C, Day CS, et al. Growth factors 
improve muscle healing in vivo. J Bone Joint Surg Br 2000; 
82: 131-7.
19) Kasemkijwattana C, Menetrey J, Bosch P, et al. Use of growth 
factors to improve muscle healing after strain injury. Clin 
Orthop Relat Res 2000; 370: 272-85. 
20) Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. 
Classification of platelet concentrates: from pure platelet-rich 
plasma (P-PRP) to leukocyte-and platelet-rich-fibrin (L-PRF). 
Trends Biotechnol 2009; 27: 158-67.
21) Mazzucco L, Balbo V, Cattana E. Not every PRP-gel is born 
equal. Evaluation of growth factor availability for tissue 
through four PRP-gel preparation: Fibrinet RegenPRP-Kit, 
Plateltex and one manual procedure. Vox Sang 2009; 97: 110-8.
22) De Vos RJ, Weir A, Van Shie HTM, et al. Platelet-rich plasma 
injection for chronic Achilles tendinopaty. A randomized 
Controlled Trial. JAMA 2010; 303: 144-9.
23) WADA 2010. The World Antidoping Code. The 2010 Prohibited 
List. World Antidoping Agency. Montreal. Available at: http://
www.wada-ama.org/rtecontent/document/2010_prohibited_
list_final_en_web.pdf. Accessed on 12/09/2012.
24) WADA 2012. The World Antidoping Code. The 2012 
Prohibited List. World Antidoping Agency. Montreal. 
Available at: http://www.wada-ama.org/Documents/World_
Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_
Prohibited_List_2012_EN.pdf. Accessed on 12/09/2012.
25) Banfi G, Corsi MM, Volpi P. Could platelet rich plasma have 
effects on systemic circulating growth factors and cytokine 
release in orthopedic applications? Br J Sport Med 2006; 40: 816. 
26) Paoloni JA, Orchard JW. The use of therapeutic medications 
for soft-tissue injuries in sports medicine. Med J Aust 2005; 
183: 384-8.  
27) Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. 
Classification of platelet concentrates: from pure platelet-rich 
plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). 
Trends Biotechnol 2009; 27: 158-67.
28) Raimondo S, Fornaro M, Di Scipio F, et al. Methods and 
protocols in peripheral nerve regeneration experimental 
research: part II-morphological techniques. Int Rev Neurobiol 
2009; 87: 81-103.
29) Geuna S. Appreciating the difference between design-based and 
model-based sampling strategies in quantitative morphology of 
the nervous system. J Comp Neurol 2000; 427: 333-9.
30) Geuna S. The revolution of counting "tops": two decades of 
the dissector principle in morphological research. Microsc 
Res Tech 2005; 66: 270-4.
31) Kaplan S, Geuna S, Ronchi G, et al. Calibration of the 
stereological estimation of the number of myelinated axons in 
the rat sciatic nerve: a multicenter study. J Neurosci Methods 
2010; 187: 90-9.
32) Tidball JG. Inflammatory cell response to acute muscle injury. 
Med Sci Sports Exerc 1995; 27: 1022-32.
33) Toumi H, Best TM. The inflammatory response: friend or 
enemy for muscle injury? Br J Sports Med 2003; 37: 284-6.
34) Chazaud B, Sonnet C, Lafuste P, et al. Satellite cells attract 
monocytes and use macrophages as a support to escape 
apoptosis and enhance muscle growth. J Cell Biol 2003; 163: 
1133-43.
35) Hirata A, Masuda S, Tamura T, et al. Expression profiling of 
cytokines and related genes in regenerating skeletal muscle 
after cardiotoxin injection: a role for osteopontin. Am J Pathol 
2003; 163: 203-15.
36) Rak J, Kerbel RS. bFGF and tumor angiogenesis: back in the 
limelight? Nat Med 1997; 3: 1083-4.
37) Brickson S, Hollander J, Corr DT, et al. Oxidant production 
and immune response after stretch injury in skeletal muscle. 
Med Sci Sports Exerc 2001; 33: 2010-5.
38) Brickson S, Ji LL, Schell K, et al. M1/70 attenuates blood-
borne neutrophil oxidants, activation and myofiber damage 
following stretch injury. J Appl Physiol 2003; 95: 969-76.
39) Schneider BS, Sannes H, Fine J, et al. Desmin characteristics 
of CD11b-positive fibers after eccentric contractions. Med Sci 
Sports Exerc 2002; 34: 274-81. 
40) St Pierre Schneider B, Brickson S, Coor DT, et al. CD11b+ 
neutrophils predominate over RAM11+ macrophages in 
stretch-injured muscle. Muscle Nerve 2002; 25: 837-44.
41) Best TM, Hunter KD. Muscle injury and repair. Phys Med 
Rehabil Clin N Am 2000; 11: 251-66.
42) Farges MC, Balcerzak D, Fisher BD, et al. Increased muscle 
proteolysis after local trauma mainly reflects macrophage-
associated lysosomal proteolysis. Am J Physiol Endocrinol 
Metab 2002; 282: E326-35.
43) Grounds MD. Towards understanding skeletal muscle 
regeneration. Pathol Res Pract 1991; 187: 1-22.
44) Hurme T, Kalimo H. Activation of myogenic precursor cells 
after muscle injury. Med Sci Sports Exerc 1992; 24: 197-205.
45) Borrione P, Di Gianfrancesco A, Pereira MT, et al. Platelet-
rich plasma in muscle healing. Am J Phys Med Rehabil 2010; 
89: 854-61.
46) Hidebrand K, Woo S, Smith D. The effect of platelet derived 
growth factors-BB on healing of the rabbit medial collateral 
ligament. An in vivo study. Am J Sports 1998; 26: 549-54.
47) Evans C. Cytokines and the role they play in the healing of 
ligaments and tendons. Sports Med 1999; 28: 71-6.
48) Molloy T, Wang Y, Murrell GA. The roles of growth factors 
in tendon and ligament healing. Sports Med 2003; 33: 381-94.
49) Gigante A, Del Torto M, Alberto B. Platelet-Rich Plasma in 
Muscle Healing. In: Doral MN, Turkey editors. Proceedings of 
5th Meeting of the European Federation of National Associations 
of Orthopedic Sports; 2008: Antalya, Turkey: p.41-42.
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
s228
Borrione P et al
Blood Transfus 2014; 12 Suppl 1: s221-8 DOI 10.2450/2013.0275-12
50) Mei-Dan OM, Mann G, Mafulli N. Platelet-rich plasma: any 
substance into it? Br J Sports Med 2010; 44: 618-9.
51) Orimo CP, Hiyamuta E, Arahata K, Sugita H. Analysis of 
inflammatory cells and complement C3 in bupivacaine-
induced myonecrosis. Muscle Nerve 1991; 14: 515-20.
52) Drago JL, Braun HJ, Durham JL, et al. Comparison of the 
acute inflammatory response of two commercial platelet-rich 
plasma systems in healthy rabbit tendons. Am J Sports Med 
2012; 40: 1274-81.
53) Asfaha S, Cenac N, Houle S, et al. Protease-activated 
receptor-4: a novel mechanism of inflammatory pain 
modulation. Br J Pharmacol 2007; 150: 176-85.
54) Aspenberg P, Virchenko O. Platelet concentrate injection 
improves Achilles tendon repair in rats. Acta Orthopaed Scand 
2004; 75: 93-9.
55) Everts P, Mahoney C, Hoffmann J. Platelet-rich plasma 
preparation using three devices: Implications for platelet 
activation and platelet growth factor release. Growth Factors 
2006; 24: 165-71.
56) Volpi P, Quaglia A, Schoenhuber H et al. Growth factors in 
the management of sport-induced tendinopathies: results after 
24 months from treatment. A pilot study. J Sport Med Phys 
Fitness 2010; 50: 494-500.
Arrived: 28 November 2012 - Revision accepted: 12 March 2013
Correspondence: Paolo Borrione
Department of Health Sciences
University of Rome "Foro Italico"
Piazza Lauro de Bosis 15
00194 Rome, Italy
e-mail: paolo.borrione@uniroma4.it
All rights reserved - For personal use only 
No other uses without permission
